Bank of New York Mellon Corp decreased its position in shares of Bruker Co. (NASDAQ:BRKR – Get Rating) by 6.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,012,050 shares of the medical research company’s stock after selling 65,301 shares during the period. Bank of New York Mellon Corp owned 0.69% of Bruker worth $53,699,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. increased its position in Bruker by 0.5% during the third quarter. BlackRock Inc. now owns 10,992,592 shares of the medical research company’s stock worth $583,269,000 after purchasing an additional 49,417 shares during the last quarter. Capital Fund Management S.A. increased its position in Bruker by 108.2% during the third quarter. Capital Fund Management S.A. now owns 121,263 shares of the medical research company’s stock worth $6,434,000 after purchasing an additional 63,008 shares during the last quarter. Royal Bank of Canada increased its position in Bruker by 67.5% during the third quarter. Royal Bank of Canada now owns 47,850 shares of the medical research company’s stock worth $2,539,000 after purchasing an additional 19,291 shares during the last quarter. Eaton Vance Management increased its position in shares of Bruker by 2.4% in the third quarter. Eaton Vance Management now owns 26,312 shares of the medical research company’s stock worth $1,396,000 after acquiring an additional 612 shares in the last quarter. Finally, Tudor Investment Corp Et Al increased its position in shares of Bruker by 89.5% in the third quarter. Tudor Investment Corp Et Al now owns 31,362 shares of the medical research company’s stock worth $1,664,000 after acquiring an additional 14,815 shares in the last quarter. Institutional investors and hedge funds own 70.40% of the company’s stock.
Insider Activity at Bruker
In related news, Director Cynthia M. Friend sold 921 shares of the firm’s stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $68.26, for a total transaction of $62,867.46. Following the completion of the sale, the director now directly owns 11,576 shares of the company’s stock, valued at approximately $790,177.76. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 27.60% of the company’s stock.
Bruker Price Performance
Bruker (NASDAQ:BRKR – Get Rating) last released its quarterly earnings results on Thursday, February 9th. The medical research company reported $0.74 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.02. The business had revenue of $708.40 million during the quarter, compared to analyst estimates of $697.68 million. Bruker had a net margin of 11.72% and a return on equity of 34.13%. The business’s revenue was up 3.6% on a year-over-year basis. During the same period last year, the business earned $0.59 EPS. Equities research analysts expect that Bruker Co. will post 2.55 EPS for the current fiscal year.
Bruker Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, March 17th. Investors of record on Wednesday, March 1st will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date of this dividend is Tuesday, February 28th. Bruker’s payout ratio is 10.05%.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on BRKR shares. Cowen dropped their price objective on shares of Bruker to $75.00 in a research report on Wednesday, November 16th. Citigroup increased their price objective on shares of Bruker from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, February 10th. One analyst has rated the stock with a sell rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $73.75.
About Bruker
Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) Life Science, BSI Nano, and Bruker Energy and Supercon Technologies (BEST).
Featured Articles
- Get a free copy of the StockNews.com research report on Bruker (BRKR)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR – Get Rating).
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.
